Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Passes Below Two Hundred Day Moving Average – What’s Next?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.55 and traded as low as $0.39. Elite Pharmaceuticals shares last traded at $0.4037, with a volume of 415,016 shares changing hands.

Elite Pharmaceuticals Trading Down 0.3%

The firm’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.55. The stock has a market cap of $434.78 million, a P/E ratio of 13.46 and a beta of 0.33. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP) last released its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.The company had revenue of $31.59 million for the quarter.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.